Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cellectis S.A. ADR (CLLS)

Cellectis S.A. ADR (CLLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 118,394
  • Shares Outstanding, K 55,584
  • Annual Sales, $ 9,190 K
  • Annual Income, $ -101,060 K
  • EBIT $ -78 M
  • EBITDA $ -60 M
  • 60-Month Beta 3.10
  • Price/Sales 12.94
  • Price/Cash Flow N/A
  • Price/Book 0.80

Options Overview Details

View History
  • Implied Volatility 355.31% ( -36.18%)
  • Historical Volatility 56.73%
  • IV Percentile 95%
  • IV Rank 90.64%
  • IV High 391.49% on 11/21/24
  • IV Low 5.12% on 03/12/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 15
  • Volume Avg (30-Day) 14
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 343
  • Open Int (30-Day) 354

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.06
  • Number of Estimates 1
  • High Estimate 0.06
  • Low Estimate 0.06
  • Prior Year -0.64
  • Growth Rate Est. (year over year) +109.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.70 +25.29%
on 11/07/24
2.15 -1.16%
on 11/27/24
+0.27 (+14.52%)
since 10/25/24
3-Month
1.70 +25.29%
on 11/07/24
2.42 -12.16%
on 08/28/24
-0.25 (-10.50%)
since 08/27/24
52-Week
1.70 +25.29%
on 11/07/24
3.77 -43.55%
on 12/20/23
-0.73 (-25.52%)
since 11/27/23

Most Recent Stories

More News
Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting

CLLS : 2.13 (-0.47%)
Cellectis Provides Business Updates and Financial Results for Third Quarter 2024

CLLS : 2.13 (-0.47%)
Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024

CLLS : 2.13 (-0.47%)
Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress

CLLS : 2.13 (-0.47%)
There's a Lot of Upside For Emerging Gene-Editing Companies

These four gene-editing companies are brand new, with very high upside potential. The industry itself is still emerging, which means more growth could come.

CRBU : 2.20 (+8.91%)
CLLS : 2.13 (-0.47%)
DTIL : 7.11 (+3.64%)
SGMO : 2.30 (+7.48%)
Pre-Market Brief: Stocks Mixed As Brutal Year Nears End

March S&P 500 futures (ESH23) are trending down -0.45% this morning after three major U.S. benchmark indices ended the regular session higher, powered by a rebound in mega-cap growth stocks as U.S. unemployment...

ESH23 : 3,957.05s (-0.09%)
META : 569.20 (-0.76%)
AAPL : 234.93 (-0.06%)
SESN : 12.5760 (+7.29%)
HOTH : 0.8300 (+3.74%)
CLLS : 2.13 (-0.47%)
ORIC : 9.97 (+1.73%)
PFE : 25.83 (+0.23%)
TGTX : 35.00 (+2.16%)
Omega Therapeutics Announces Appointment of Rainer Boehm to its Board of Directors

/PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to using...

CLLS : 2.13 (-0.47%)
HGEN : 0.0002 (-84.62%)
OMGA : 0.7958 (-0.08%)
Cellectis Provides Business Update and Reports Financial Results for Second Quarter 2022

  IND clearance received from FDA for UCART20x22 for the treatment of Non-Hodgkin LymphomaCellectis unveiled novel immune-evasive universal allogeneic CAR...

CLLS : 2.13 (-0.47%)
Cellectis Receives IND clearance for UCART20x22, its First in-house Manufactured Product Candidate for the Treatment of B-cell Malignancies

UCART20x22 is Cellectis’ first allogeneic dual CAR T, targeting CD20 and CD22 simultaneously UCART20x22 is Cellectis’ first product candidate fully...

CLLS : 2.13 (-0.47%)
Cellectis to Report Second Quarter 2022 Financial Results

NEW YORK, July 28, 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its...

CLLS : 2.13 (-0.47%)

Business Summary

Cellectis SA is a gene-editing company. The company focused on developing immunotherapies based on gene edited engineered CAR-T cells. Cellectis SA is based in Paris, France.

See More

Key Turning Points

3rd Resistance Point 2.23
2nd Resistance Point 2.19
1st Resistance Point 2.16
Last Price 2.13
1st Support Level 2.10
2nd Support Level 2.06
3rd Support Level 2.03

See More

52-Week High 3.77
Fibonacci 61.8% 2.98
Fibonacci 50% 2.74
Fibonacci 38.2% 2.49
Last Price 2.13
52-Week Low 1.70

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar